Barclays analyst Gena Wang has revised the price target for 4D Molecular (FDMT, Financial), reducing it from $45 to $38. Despite this adjustment, the analyst maintains an Overweight rating on the company's shares. This update follows the firm's reassessment of 4D Molecular's financial model after their first-quarter report.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for 4D Molecular Therapeutics Inc (FDMT, Financial) is $29.22 with a high estimate of $51.00 and a low estimate of $6.00. The average target implies an upside of 801.92% from the current price of $3.24. More detailed estimate data can be found on the 4D Molecular Therapeutics Inc (FDMT) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, 4D Molecular Therapeutics Inc's (FDMT, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for 4D Molecular Therapeutics Inc (FDMT, Financial) in one year is $0.05, suggesting a downside of 98.46% from the current price of $3.24. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the 4D Molecular Therapeutics Inc (FDMT) Summary page.
